2026-05-09

NATURAL GAS - speculators net long (+3.0σ vs 52w mean) - contrarian bear signal

OSINT: Putin Views Germany's Schröder as EU Lead on Ukraine Talks

OSINT: Peter Magyar Sworn In, Ending Orbán's 16-Year Rule in Hungary

OSINT: Markets price in extended Fed pause, cuts delayed to Dec 2027

OSINT: Ukrainian Air Force MiG‑29 Fulcrum flies mission over contested zone

COPPER - speculators net long (+2.1σ vs 52w mean) - contrarian bear signal

ETH ETF outflow of $104M - institutional selling

ETH ETF outflow of $104M - institutional selling

USDC/USDT has $313.0M volume but only $884K liquidity - thin market, slippage risk

BURNIE/SOL crashed -41.5% in 24h on pumpswap DEX

USDC/USDT has $316.3M volume but only $884K liquidity - thin market, slippage risk

RIV/SOL crashed -70.7% in 24h on meteora DEX

SOL RSI 70.8 - overbought (crossed above 70)

ETH DEX volume/liquidity ratio elevated (0.55x) - strong on-chain trading activity

ETH DEX volume/liquidity ratio elevated (0.76x) - strong on-chain trading activity

SOL RSI 71.4 - overbought (crossed above 70)

SOL DEX volume/liquidity ratio elevated (1.20x) - strong on-chain trading activity

OSINT: Ethereum's DeFi TVL Share Drops to 54% but Holds $45.4B

ETH DEX volume/liquidity ratio elevated (0.83x) - strong on-chain trading activity

FDA approves drug (Pfizer) - new revenue stream

FDA approves drug (Pfizer) - new revenue stream

FDA approves drug (Pfizer) - new revenue stream

FDA approves drug (Pfizer) - new revenue stream

FDA approves CYTOTEC (Pfizer) - new revenue stream

FDA approves drug (Pfizer) - new revenue stream

FDA approves CYTOTEC (Pfizer) - new revenue stream

FDA approves CYTOTEC (Pfizer) - new revenue stream

FDA approves drug (Lilly) - new revenue stream

FDA approves LASTACAFT (AbbVie) - new revenue stream

FDA approves LASTACAFT (AbbVie) - new revenue stream

FDA approves SYNTHROID (AbbVie) - new revenue stream

FDA approves SYNTHROID (AbbVie) - new revenue stream

FDA approves LASTACAFT (AbbVie) - new revenue stream

FDA approves SYNTHROID (AbbVie) - new revenue stream

FDA approves drug (Abbott) - new revenue stream

FDA approves drug (Abbott) - new revenue stream

FDA approves drug (Abbott) - new revenue stream

FDA approves drug (Abbott) - new revenue stream

FDA approves drug (Abbott) - new revenue stream

FDA approves drug (Abbott) - new revenue stream

FDA approves drug (Abbott) - new revenue stream

Debt issued for acquisition financing - deal likely imminent

SPY RSI 73.8 - overbought (crossed above 70)

Cognizant search volume spiked +60 pts - unusual interest

CrowdStrike search volume spiked +68 pts - unusual interest

Baker Hughes search volume spiked +75 pts - unusual interest

MPC job postings down -85% WoW - potential restructuring

DASH job postings down -47% WoW - potential restructuring

BRO job postings down -50% WoW - potential restructuring

1 congress member filed 5 trades in TDG: net buying (5B/0S)

DaVita search volume spiked +43 pts - unusual interest

Elevance Health search volume spiked +68 pts - unusual interest

SPY RSI 73.8 - overbought (crossed above 70)

General Motors search volume spiked +56 pts - unusual interest

Baker Hughes search volume spiked +75 pts - unusual interest

Cognizant search volume spiked +60 pts - unusual interest

CrowdStrike search volume spiked +68 pts - unusual interest

MPC job postings down -85% WoW - potential restructuring

DASH job postings down -47% WoW - potential restructuring

BRO job postings down -50% WoW - potential restructuring

1 congress member filed 5 trades in TDG: net buying (5B/0S)

Q4-2025: Beat consensus by 6.2% - EPS $3.65 vs $3.4368 estimate

Q1-2026: Beat consensus by 10.5% - EPS $4.13 vs $3.7391 estimate

Q2-2025: Beat consensus by 5.8% - EPS $2.13 vs $2.0138 estimate

Q1-2026: Beat consensus by 10.9% - EPS $3.43 vs $3.0922 estimate

Q4-2025: Beat consensus by 6.8% - EPS $2.68 vs $2.5099 estimate

Beat consensus by 29.3% - EPS $2.8 vs $2.166 estimate

Q4-2025: Beat consensus by 5.4% - EPS $2.12 vs $2.0111 estimate

Q4-2025: Beat consensus by 21.7% - EPS $-2.11 vs $-2.6953 estimate

Q1-2026: Beat consensus by 15.8% - EPS $-3.4 vs $-4.0402 estimate

Q2-2025: Beat consensus by 29.6% - EPS $-2.13 vs $-3.0257 estimate

Q3-2025: Beat consensus by 76.3% - EPS $-0.51 vs $-2.1494 estimate

Q1-2026: Beat consensus by 16.0% - EPS $-1.28 vs $-1.5238 estimate

Q3-2025: Beat consensus by 13.1% - EPS $2.68 vs $2.3705 estimate

Q2-2025: Beat consensus by 7.7% - EPS $2.19 vs $2.0337 estimate

Q1-2026: Beat consensus by 118.6% - EPS $1.65 vs $0.7548 estimate

Q2-2025: Beat consensus by 19.2% - EPS $3.96 vs $3.3233 estimate

Q3-2025: Missed consensus by 5.3% - EPS $3.01 vs $3.1789 estimate

Q4-2025: Beat consensus by 40.0% - EPS $4.07 vs $2.9062 estimate

Q4-2025: Missed consensus by 53.3% - EPS $0.22 vs $0.4707 estimate

Q1-2025: Beat consensus by 8.5% - EPS $0.49 vs $0.4517 estimate

Missed consensus by 30.5% - EPS $0.51 vs $0.734 estimate

Q1-2026: Beat consensus by 7.8% - EPS $0.58 vs $0.5378 estimate

Q3-2025: Beat consensus by 13.7% - EPS $0.56 vs $0.4927 estimate

Q2-2025: Beat consensus by 6.2% - EPS $2.16 vs $2.0342 estimate

Q1-2026: Beat consensus by 6.8% - EPS $2.14 vs $2.0045 estimate

Q1-2026: Beat consensus by 9.9% - EPS $0.66 vs $0.6004 estimate

Q1-2026: Missed consensus by 9.2% - EPS $0.49 vs $0.5398 estimate

Q2-2025: Beat consensus by 47.4% - EPS $0.79 vs $0.5361 estimate

Q3-2025: Missed consensus by 40.2% - EPS $0.24 vs $0.4013 estimate

Q4-2025: Beat consensus by 5.7% - EPS $8.88 vs $8.3992 estimate

Beat consensus by 5.6% - EPS $7.31 vs $6.923 estimate

Q2-2025: Beat consensus by 18.3% - EPS $7.14 vs $6.0352 estimate

Q3-2025: Beat consensus by 6.2% - EPS $7.25 vs $6.8245 estimate

Q4-2025: Beat consensus by 9.1% - EPS $2.58 vs $2.3656 estimate

Missed consensus by 6.9% - EPS $2.02 vs $2.169 estimate

Q1-2026: Beat consensus by 5.5% - EPS $2.42 vs $2.2941 estimate

Q2-2025: Beat consensus by 5.6% - EPS $0.73 vs $0.6916 estimate

Beat consensus by 8.1% - EPS $0.67 vs $0.62 estimate

Q4-2025: Beat consensus by 5.4% - EPS $3.64 vs $3.4524 estimate

Q3-2025: Beat consensus by 5.6% - EPS $3.92 vs $3.7137 estimate

Q2-2026: Beat consensus by 8.0% - EPS $9.86 vs $9.1295 estimate

Q4-2026: Beat consensus by 10.6% - EPS $0.57 vs $0.5154 estimate

Q1-2026: Beat consensus by 11.8% - EPS $0.27 vs $0.2415 estimate

Q1-2026: Beat consensus by 17.6% - EPS $1.04 vs $0.8841 estimate

Q3-2025: Missed consensus by 7.0% - EPS $0.97 vs $1.0433 estimate

Q2-2025: Beat consensus by 18.5% - EPS $1.3 vs $1.0973 estimate

Q1-2026: Beat consensus by 5.5% - EPS $2.72 vs $2.5792 estimate

Q3-2025: Missed consensus by 7.0% - EPS $0.84 vs $0.9034 estimate

Missed consensus by 48.2% - EPS $0.48 vs $0.927 estimate

Q2-2025: Beat consensus by 5.3% - EPS $0.92 vs $0.8737 estimate

Q1-2026: Beat consensus by 31.0% - EPS $1.06 vs $0.8091 estimate

Q4-2025: Beat consensus by 8.8% - EPS $4.76 vs $4.3756 estimate

Q2-2025: Missed consensus by 60.1% - EPS $0.41 vs $1.0281 estimate

Q3-2025: Missed consensus by 48.0% - EPS $0.73 vs $1.4042 estimate

Q1-2026: Beat consensus by 36.0% - EPS $-0.32 vs $-0.4999 estimate

Q4-2025: Missed consensus by 299.7% - EPS $-0.26 vs $0.1302 estimate

Q1-2026: Beat consensus by 140.4% - EPS $0.49 vs $0.2038 estimate

Q3-2025: Beat consensus by 24.2% - EPS $1.01 vs $0.8134 estimate

Missed consensus by 23.5% - EPS $0.62 vs $0.81 estimate

Q1-2026: Beat consensus by 19.0% - EPS $0.91 vs $0.7644 estimate

Q4-2025: Beat consensus by 10.9% - EPS $0.85 vs $0.7663 estimate

Q2-2025: Beat consensus by 48.2% - EPS $0.79 vs $0.5329 estimate

Q3-2025: Beat consensus by 28.5% - EPS $0.78 vs $0.6068 estimate

Q1-2026: Missed consensus by 5.8% - EPS $0.45 vs $0.4778 estimate

Q2-2025: Missed consensus by 16.1% - EPS $0.43 vs $0.5123 estimate

Q3-2026: Beat consensus by 12.6% - EPS $2.59 vs $2.2996 estimate

Beat consensus by 5.6% - EPS $3.1 vs $2.935 estimate

Q2-2026: Beat consensus by 6.4% - EPS $1.27 vs $1.1935 estimate

Q4-2025: Beat consensus by 7.8% - EPS $1.33 vs $1.2338 estimate

Q1-2026: Beat consensus by 7.1% - EPS $0.87 vs $0.8122 estimate

Q2-2025: Beat consensus by 5.1% - EPS $0.68 vs $0.6473 estimate

Q3-2025: Missed consensus by 6.9% - EPS $1.12 vs $1.2024 estimate

Beat consensus by 29.0% - EPS $7.43 vs $5.76 estimate

Q2-2025: Beat consensus by 12.0% - EPS $7.29 vs $6.5072 estimate

Missed consensus by 5.2% - EPS $6.44 vs $6.793 estimate

Q3-2025: Beat consensus by 8.2% - EPS $6.95 vs $6.4242 estimate

Elevance Health search volume spiked +68 pts - unusual interest

Beat consensus by 5.1% - EPS $4.24 vs $4.033 estimate

Q3-2025: Beat consensus by 7.8% - EPS $4.82 vs $4.4695 estimate

Q2-2025: Beat consensus by 5.5% - EPS $3.57 vs $3.3838 estimate

DASH job postings down -47% WoW - potential restructuring

Q1-2026: Beat consensus by 6.5% - EPS $1.14 vs $1.0708 estimate

Q4-2025: Missed consensus by 19.9% - EPS $0.32 vs $0.3993 estimate

Q1-2026: Beat consensus by 174.7% - EPS $1.13 vs $0.4114 estimate

Q2-2025: Missed consensus by 38.8% - EPS $0.22 vs $0.3593 estimate

Q1-2026: Beat consensus by 17.0% - EPS $0.22 vs $0.1881 estimate

Q2-2026: Beat consensus by 14.2% - EPS $0.4 vs $0.3503 estimate

Q3-2026: Beat consensus by 12.1% - EPS $0.21 vs $0.1874 estimate

Q4-2025: Beat consensus by 13.6% - EPS $121.54 vs $106.9641 estimate

Q1-2026: Missed consensus by 12.2% - EPS $67.76 vs $77.1366 estimate

Q3-2025: Beat consensus by 19.1% - EPS $2.63 vs $2.2085 estimate

Q1-2026: Beat consensus by 13.5% - EPS $3.23 vs $2.8448 estimate

Q4-2025: Missed consensus by 10.3% - EPS $1.73 vs $1.9291 estimate

Q4-2025: Beat consensus by 11.5% - EPS $2.69 vs $2.4134 estimate

Beat consensus by 14.3% - EPS $2.71 vs $2.37 estimate

Q2-2026: Beat consensus by 6.6% - EPS $2.05 vs $1.9234 estimate

Q4-2025: Beat consensus by 15.4% - EPS $3.22 vs $2.7892 estimate

Q2-2025: Beat consensus by 6.6% - EPS $1.68 vs $1.5759 estimate

Q3-2025: Beat consensus by 29.7% - EPS $2.75 vs $2.1197 estimate

Q1-2026: Missed consensus by 16.1% - EPS $1.48 vs $1.7643 estimate

Q4-2025: Beat consensus by 6.5% - EPS $1.03 vs $0.9667 estimate

Q2-2025: Beat consensus by 13.4% - EPS $0.818 vs $0.7211 estimate

Q3-2025: Beat consensus by 11.8% - EPS $0.964 vs $0.8619 estimate

Q3-2025: Beat consensus by 17.6% - EPS $7.67 vs $6.5201 estimate

Q4-2025: Beat consensus by 7.5% - EPS $0.14 vs $0.1302 estimate

Q2-2026: Beat consensus by 39.2% - EPS $0.53 vs $0.3807 estimate

Q3-2026: Beat consensus by 22.9% - EPS $0.35 vs $0.2848 estimate

Q1-2026: Beat consensus by 78.1% - EPS $0.49 vs $0.2752 estimate

Q3-2025: Missed consensus by 6.8% - EPS $0.19 vs $0.2038 estimate

Q1-2026: Missed consensus by 10.2% - EPS $0.7 vs $0.7791 estimate

Q3-2025: Missed consensus by 17.4% - EPS $0.587 vs $0.7106 estimate

Q2-2025: Beat consensus by 20.4% - EPS $1.43 vs $1.1873 estimate

Q1-2026: Beat consensus by 31.7% - EPS $2.9 vs $2.2019 estimate

Q4-2025: Beat consensus by 24.7% - EPS $2.52 vs $2.0209 estimate

Q3-2025: Beat consensus by 18.3% - EPS $1.71 vs $1.4454 estimate

Q1-2026: Beat consensus by 12.5% - EPS $1.09 vs $0.9692 estimate

Q3-2025: Beat consensus by 10.0% - EPS $1.13 vs $1.0269 estimate

Q4-2025: Beat consensus by 5.3% - EPS $0.28 vs $0.2658 estimate

Q1-2026: Beat consensus by 58.3% - EPS $0.23 vs $0.1453 estimate

Beat consensus by 15.8% - EPS $1.91 vs $1.649 estimate

Q2-2026: Beat consensus by 27.3% - EPS $12.2 vs $9.5849 estimate

Beat consensus by 17.4% - EPS $4.78 vs $4.072 estimate

General Motors search volume spiked +56 pts - unusual interest

SPY RSI 73.8 - overbought (crossed above 70)

Baker Hughes search volume spiked +75 pts - unusual interest

CrowdStrike search volume spiked +68 pts - unusual interest

1 congress member filed 5 trades in TDG: net buying (5B/0S)

Cognizant search volume spiked +60 pts - unusual interest

FDX job postings down -46% WoW - potential restructuring

BRO job postings down -50% WoW - potential restructuring

MPC job postings down -85% WoW - potential restructuring

OSINT: Ethereum's DeFi TVL Share Drops to 54% but Holds $45.4B

OSINT: Neuralink unveils laser‑milled needle tech for brain implants

Elevance Health search volume spiked +68 pts - unusual interest

American Water Works search volume spiked +100 pts - unusual interest

DASH job postings down -47% WoW - potential restructuring

DXY -0.42% - dollar weakness signal

DXY -0.42% - dollar weakness signal

DXY -0.42% - dollar weakness signal